Physiomics PLC Contract award
11 May 2021 - 4:00PM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
11 May 2021
11 May 2021
Physiomics plc
("Physiomics") or ("the Company")
Contract award
Physiomics plc (AIM: PYC), the consultancy using mathematical
models to support the development of drug treatment regimens and
personalised medicine solutions, is pleased to announce that it has
been awarded a first contract by new client Numab Therapeutics
("Numab"). Numab is an exciting young biopharmaceutical company
based in Zurich, Switzerland which is developing multi-specific
biotherapeutics for chronic inflammation and cancer. Physiomics has
recent significant experience of the mathematical modelling of
multi-specific pharmaceuticals which it will bring to bear on an
undisclosed Numab compound in this project that is expected to last
around three months.
Physiomics CEO, Dr Jim Millen, commented : "We are delighted
that Numab has selected Physiomics to support them with one of
their new programs and look forward to working with their highly
talented team."
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 80 projects, involving over 40 targets and
70 drugs, and has worked with clients such as Merck KGaA, Astellas,
Merck & Co and Bicycle Therapeutics.
About Numab Therapeutics
Numab Therapeutics is an oncology-focused biopharmaceutical
company based in the Zurich area, Switzerland. Numab is writing the
next chapter in cancer immunotherapy by creating multi-specific
antibodies that enable the pursuit of novel therapeutic strategies.
With its proprietary MATCH technology platform, it is fuelling a
new wave of multi-specific drug candidates engineered with
versatility and developability in mind. Numab Therapeutics believes
that meeting the highest quality standards in every step of the
drug design process matters will result in better patient outcomes.
For further information, visit www.numab.com.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGPUCGAUPGGQU
(END) Dow Jones Newswires
May 11, 2021 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2024 to May 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From May 2023 to May 2024